A Phase 1/2 interventional study of Setmelanotide and Placebo in Overweight and Obesity, sponsored by Rhythm Pharmaceuticals, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-08-07.
Sponsored by Rhythm Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing setmelanotide in Obesity — 1 open to participants now, 2 under way, none of them phase 3. setmelanotide · Obesity.
Among the 16 studies testing setmelanotide in Obesity, this one is the 5th largest by enrollment, is the only one that started in 2014, is the only one in phase 1/2, and was the 2nd registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →1 of the 16 studies testing setmelanotide in Obesity is open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
By country, each count listing its studies:
setmelanotide: first FDA approval 2020 (IMCIVREE), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 8 · Phase 3 7
First in 2012; this study’s year is marked. 1 started in 2014.
This study's enrollment of 99 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 34 across the 16 interventional studies. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 16 have an industry lead sponsor. The 2 most frequent:
Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
19 studies in Obesity by Rhythm Pharmaceuticals, Inc.: none open now, 2 under way, none of them phase 3. Of 16 finished, 10 (63%) have results posted.
Among the 19 studies in Obesity by Rhythm Pharmaceuticals, Inc., this one is the 6th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2014, is one of 2 in phase 1/2, and was the 2nd registered.
Rhythm Pharmaceuticals, Inc.’s Obesity studies by the year they started, since 2012.
1 of the studies testing setmelanotide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07496463Massachusetts General HospitalSetmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies testing setmelanotide in Obesity, from their registry updates:
Among Rhythm Pharmaceuticals, Inc.’s 19 in Obesity:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effects of a new daily subcutaneous (SC) injectable formulation of setmelanotide (RM-493) in healthy participants with obesity on mean percent body weight loss and other weight loss parameters, as well as pharmacokinetic (PK) profile. The study is designed to evaluate the efficacy and tolerability of setmelanotide administered once or twice daily. The study drug (setmelanotide and placebo) will be administered in a blinded fashion.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's enrollment of 99 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →Rhythm Pharmaceuticals, Inc. is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 19 completed or terminated interventional studies of FDA-regulated products, 15 (79%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with a history of the following:
Use of prescription medications on a regular basis with the following exceptions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Once daily in the morning, equivalent placebo in evening.
Drug: Setmelanotide · Drug: Placebo
Split dose, one half in the morning and one half in the evening.
Drug: Setmelanotide
Placebo in the morning, placebo in the evening.
Drug: Placebo
Also known as: RM-493
Body Weight - Stage A
Time frame: Baseline
Percent Change From Baseline in Body Weight at Week 12 - Stage A
Time frame: Baseline, Week 12
Body Weight - Stage B
Time frame: Baseline
Percent Change From Baseline in Body Weight at Week 12 - Stage B
Time frame: Baseline, Week 12
Body Weight - Stage C
Time frame: Baseline
Percent Change From Baseline in Body Weight at Week 12 - Stage C
Time frame: Baseline, Week 12
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) - Stage A
An adverse event (AE) was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs.
Time frame: From first dose up to Day 114
Number of Participants With TEAEs - Stage B
An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs.
Time frame: From first dose up to Day 114
Number of Participants With TEAEs - Stage C
An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs.
Time frame: From first dose up to Day 114
Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage A
Time frame: Predose (0 hours) and at 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 22, and 24 hours after dosing on Day 8
Mean Setmelanotide Concentrations During a 24-Hour Steady State Interval on Day 8 - Stage C
Time frame: Predose (0 hours) and at 1, 2, 4, 6, 8, 10, 12, 14 and 24 hours after dosing on Day 8
Change From Baseline in Ambulatory Blood Pressure Monitoring (ABPM) Parameters During 24-Hour Interval Between Days 8 and 15 - Stage A
The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for all participants in Stage A. Change from Baseline in ABPM parameters (systolic blood pressure \[SBP\], diastolic blood pressure \[DBP\], pulse pressure, mean arterial pressure \[MAP\]) during 24-hour interval between Days 8 and 15 is presented.
Time frame: Baseline and for one 24-hour interval between Days 8 or 15
Change From Baseline in ABPM Parameters During 24-Hour Interval Between Days 8 and 15 - Stage C
The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for a subset of participants in Stage C. Change from Baseline in ABPM parameters (SBP, DBP, pulse pressure, MAP) during 24-hour interval between Days 8 and 15 is presented.
Time frame: Baseline and for one 24-hour interval between Days 8 or 15
Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage A
The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for all participants in Stage A. Change from Baseline in heart rate during 24-hour interval between Days 8 and 15 is presented.
Time frame: Baseline and for one 24-hour interval between Days 8 and 15
Change From Baseline in Heart Rate Using ABPM During 24-Hour Interval Between Days 8 and 15 - Stage C
The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for a subset of participants in Stage C. Change from Baseline in heart rate during 24-hour interval between Days 8 and 15 is presented.
Time frame: Baseline and for one 24-hour interval between Days 8 and 15
| Milestone | Stage A: Setmelanotide 0.75 mg BID | Stage A: Setmelanotide 1.5 mg QD | Stage A: Placebo 0.75 mg BID | Stage A: Placebo 1.5 mg QD | Stage B: Setmelanotide 1.5 mg QD | Stage B: Placebo 1.5 mg QD | Stage C: Setmelanotide 2 mg QD | Stage C: Placebo 2 mg QD |
|---|---|---|---|---|---|---|---|---|
| Started | 10 | 9 | 3 | 3 | 11 | 6 | 29 | 28 |
| Completed | 8 | 6 | 3 | 3 | 10 | 6 | 22 | 25 |
| Not completed | 2 | 3 | 0 | 0 | 1 | 0 | 7 | 3 |
| Withdrew: Adverse event | 1 | 2 | 0 | 0 | 0 | 0 | 3 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 3 |
| Withdrew: Unable to comply with study visits | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| Kilograms (kg) | Stage A: Setmelanotide 0.75 mg BID | Stage A: Setmelanotide 1.5 mg QD | Stage A: Placebo |
|---|---|---|---|
| Body Weight - Stage A | 101.7 ± 5.09 | 101.7 ± 4.24 | 94.5 ± 3.85 |
| percent change | Stage A: Setmelanotide 0.75 mg BID | Stage A: Setmelanotide 1.5 mg QD | Stage A: Placebo |
|---|---|---|---|
| Percent Change From Baseline in Body Weight at Week 12 - Stage A | -1.38 (-3.27 to 0.52) | -0.74 (-2.77 to 1.28) | 2.89 (0.53 to 5.25) |
| kg | Stage B: Setmelanotide 1.5 mg QD | Stage B: Placebo 1.5 mg QD |
|---|---|---|
| Body Weight - Stage B | 99.4 ± 3.51 | 93.3 ± 2.92 |
| percent change | Stage B: Setmelanotide 1.5 mg QD | Stage B: Placebo 1.5 mg QD |
|---|---|---|
| Percent Change From Baseline in Body Weight at Week 12 - Stage B | -1.29 (-2.47 to -0.11) | 2.28 (0.68 to 3.88) |
| Kg | Stage C: Setmelanotide 2 mg QD | Stage C: Placebo 2 mg QD |
|---|---|---|
| Body Weight - Stage C | 98.5 ± 1.87 | 98.7 ± 2.44 |
| percent change | Stage C: Setmelanotide 2 mg QD | Stage C: Placebo 2 mg QD |
|---|---|---|
| Percent Change From Baseline in Body Weight at Week 12 - Stage C | -2.28 (-3.32 to -1.25) | -0.06 (-1.08 to 0.95) |
An adverse event (AE) was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs.
| Participants | Stage A: Setmelanotide 0.75 mg BID | Stage A: Setmelanotide 1.5 mg QD | Stage A: Placebo 0.75 mg BID | Stage A: Placebo 1.5 mg QD |
|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) - Stage A | 10 | 8 | 2 | 3 |
An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs.
| Participants | Stage B: Setmelanotide 1.5 mg QD | Stage B: Placebo 1.5 mg QD |
|---|---|---|
| Number of Participants With TEAEs - Stage B | 9 | 3 |
An AE was any untoward medical occurrence in a clinical trial participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. AEs that occurred after the start of study drug administration were considered TEAEs.
| Participants | Stage C: Setmelanotide 2 mg QD | Stage C: Placebo 2 mg QD |
|---|---|---|
| Number of Participants With TEAEs - Stage C | 29 | 21 |
| nanograms per milliliter (ng/mL) | Stage A: Setmelanotide 0.75 mg BID | Stage A: Setmelanotide 1.5 mg QD |
|---|---|---|
| Predose (0 hours) | 7.24 ± 2.52 | 3.54 ± 0.949 |
| 1 hour postdose | 9.18 ± 3.04 | 8.51 ± 3.07 |
| 2 hours postdose | 10.8 ± 3.93 | 13.0 ± 5.75 |
| 4 hours postdose | 13.9 ± 5.05 | 18.0 ± 6.26 |
| 6 hours postdose | 11.8 ± 5.02 | 20.6 ± 5.27 |
| 8 hours postdose | 9.86 ± 3.66 | 19.8 ± 3.19 |
| 10 hours postdose | 7.48 ± 3.18 | 15.5 ± 2.46 |
| 12 hours postdose | 6.02 ± 2.49 | 11.1 ± 1.63 |
| 14 hours postdose | 10.6 ± 5.65 | 9.15 ± 1.29 |
| 16 hours postdose | 13.6 ± 6.96 | 7.32 ± 1.15 |
| 20 hours postdose | 9.26 ± 3.86 | 5.23 ± 0.991 |
| 22 hours postdose | 7.43 ± 3.32 | 4.41 ± 0.945 |
| 24 hours postdose | 5.74 ± 2.72 | 3.58 ± 0.900 |
| ng/mL | Stage C: Setmelanotide 2 mg QD |
|---|---|
| Predose (0 hours) | 5.03 ± 1.84 |
| 1 hour postdose | 12.3 ± 3.99 |
| 2 hours postdose | 18.1 ± 6.23 |
| 4 hours postdose | 24.2 ± 8.19 |
| 6 hours postdose | 26.5 ± 7.32 |
| 8 hours postdose | 24.0 ± 5.88 |
| 10 hours postdose | 18.1 ± 3.76 |
| 12 hours postdose | 13.9 ± 3.35 |
| 14 hours postdose | 11.2 ± 2.47 |
| 24 hours postdose | 4.74 ± 1.66 |
The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for all participants in Stage A. Change from Baseline in ABPM parameters (systolic blood pressure \[SBP\], diastolic blood pressure \[DBP\], pulse pressure, mean arterial pressure \[MAP\]) during 24-hour interval between Days 8 and 15 is presented.
| millimeters of mercury (mmHg) | Stage A: Setmelanotide 0.75 mg BID | Stage A: Setmelanotide 1.5 mg QD | Stage A: Placebo 0.75 mg BID | Stage A: Placebo 1.5 mg QD |
|---|---|---|---|---|
| Baseline: SBP | 121.09 ± 7.18 | 119.89 ± 10.36 | 115.31 ± 3.81 | 117.01 ± 10.09 |
| Change at 24-hour interval between Days 8 and 15: SBP | -4.08 ± 6.55 | -2.23 ± 3.95 | -0.67 ± 4.61 | -1.08 ± 2.90 |
| Baseline: DBP | 71.02 ± 5.03 | 73.09 ± 9.22 | 70.48 ± 1.35 | 71.08 ± 8.81 |
| Change at 24-hour interval between Days 8 and 15: DBP | -2.13 ± 3.93 | -1.55 ± 2.63 | 0.58 ± 3.42 | -1.90 ± 2.47 |
| Baseline: Pulse pressure | 50.07 ± 4.77 | 46.79 ± 5.31 | 44.83 ± 3.20 | 45.93 ± 2.07 |
| Change at 24-hour interval between Days 8 and 15: Pulse pressure | -1.94 ± 3.89 | -0.68 ± 2.32 | -1.25 ± 3.10 | 0.82 ± 0.77 |
| Baseline: MAP | 88.27 ± 5.50 | 89.05 ± 8.69 | 85.45 ± 2.05 | 86.85 ± 8.34 |
| Change at 24-hour interval between Days 8 and 15: MAP | -2.73 ± 4.42 | -1.98 ± 2.81 | 0.44 ± 3.46 | -1.63 ± 2.67 |
The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for a subset of participants in Stage C. Change from Baseline in ABPM parameters (SBP, DBP, pulse pressure, MAP) during 24-hour interval between Days 8 and 15 is presented.
| mmHg | Stage C: Setmelanotide 2 mg QD | Stage C: Placebo 2 mg QD |
|---|---|---|
| Baseline: SBP | 117.57 ± 9.99 | 117.51 ± 8.05 |
| Change at 24-hour interval between Days 8 and 15: SBP | 1.63 ± 6.83 | 1.22 ± 6.28 |
| Baseline: DBP | 68.90 ± 7.57 | 69.92 ± 5.96 |
| Change at 24-hour interval between Days 8 and 15: DBP | 1.77 ± 4.83 | 0.83 ± 4.32 |
| Baseline: Pulse pressure | 48.67 ± 7.46 | 47.59 ± 7.58 |
| Change at 24-hour interval between Days 8 and 15: Pulse pressure | -0.14 ± 3.39 | 0.38 ± 2.70 |
| Baseline: MAP | 85.97 ± 7.33 | 86.30 ± 5.23 |
| Change at 24-hour interval between Days 8 and 15: MAP | 1.21 ± 5.35 | 0.68 ± 4.56 |
The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for all participants in Stage A. Change from Baseline in heart rate during 24-hour interval between Days 8 and 15 is presented.
| beats per minute (bpm) | Stage A: Setmelanotide 0.75 mg BID | Stage A: Setmelanotide 1.5 mg QD | Stage A: Placebo 0.75 mg BID | Stage A: Placebo 1.5 mg QD |
|---|---|---|---|---|
| Baseline | 79.28 ± 7.05 | 77.55 ± 8.21 | 72.92 ± 6.80 | 68.10 ± 6.48 |
| Change at 24-hour interval between Days 8 and 15 | -0.90 ± 3.87 | -2.70 ± 5.38 | -5.75 ± 7.72 | 1.35 ± 7.70 |
The 24-hour ABPM parameters were obtained twice once at Baseline and once during 24-hour interval between Days 8 and 15 for a subset of participants in Stage C. Change from Baseline in heart rate during 24-hour interval between Days 8 and 15 is presented.
| bpm | Stage C: Setmelanotide 2 mg QD | Stage C: Placebo 2 mg QD |
|---|---|---|
| Baseline | 80.77 ± 9.03 | 73.01 ± 10.65 |
| Change at 24-hour interval between Days 8 and 15 | -0.95 ± 9.78 | 0.98 ± 4.21 |
Collected over From first dose up to Day 114. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage A: Setmelanotide 0.75 mg BID | 0/10 (0%) | 0/10 (0%) | 10/10 (100%) |
| Stage A: Setmelanotide 1.5 mg QD | 0/9 (0%) | 0/9 (0%) | 8/9 (88.9%) |
| Stage A: Placebo 0.75 mg BID | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Stage A: Placebo 1.5 mg QD | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Stage B: Setmelanotide 1.5 mg QD | 0/11 (0%) | 0/11 (0%) | 9/11 (81.8%) |
| Stage B: Placebo 1.5 mg QD | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Stage C: Setmelanotide 2 mg QD | 0/29 (0%) | 1/29 (3.4%) | 29/29 (100%) |
| Stage C: Placebo 2 mg QD | 0/28 (0%) | 1/28 (3.6%) | 21/28 (75%) |
| Event | Stage A: Setmelanotide 0.75 mg BID | Stage A: Setmelanotide 1.5 mg QD | Stage A: Placebo 0.75 mg BID | Stage A: Placebo 1.5 mg QD | Stage B: Setmelanotide 1.5 mg QD | Stage B: Placebo 1.5 mg QD | Stage C: Setmelanotide 2 mg QD | Stage C: Placebo 2 mg QD |
|---|---|---|---|---|---|---|---|---|
| Muscle strainInjury, poisoning and procedural complications | 0/10 | 0/9 | 0/3 | 0/3 | 0/11 | 0/6 | 0/29 | 1/28 |
| Chest painGeneral disorders | 0/10 | 0/9 | 0/3 | 0/3 | 0/11 | 0/6 | 1/29 | 0/28 |
| Event | Stage A: Setmelanotide 0.75 mg BID | Stage A: Setmelanotide 1.5 mg QD | Stage A: Placebo 0.75 mg BID | Stage A: Placebo 1.5 mg QD | Stage B: Setmelanotide 1.5 mg QD | Stage B: Placebo 1.5 mg QD | Stage C: Setmelanotide 2 mg QD | Stage C: Placebo 2 mg QD |
|---|---|---|---|---|---|---|---|---|
| Skin hyperpigmentationSkin and subcutaneous tissue disorders | 7/10 | 6/9 | 1/3 | 0/3 | 8/11 | 0/6 | 26/29 | 2/28 |
| NauseaGastrointestinal disorders | 3/10 | 6/9 | 0/3 | 1/3 | 6/11 | 1/6 | 17/29 | 3/28 |
| HeadacheNervous system disorders | 5/10 | 4/9 | 0/3 | 0/3 | 4/11 | 2/6 | 16/29 | 9/28 |
| VomitingGastrointestinal disorders | 1/10 | 4/9 | 0/3 | 0/3 | 3/11 | 1/6 | 10/29 | 3/28 |
| Injection site pruritusGeneral disorders | 4/10 | 2/9 | 0/3 | 0/3 | 2/11 | 0/6 | 5/29 | 0/28 |
| FatigueGeneral disorders | 3/10 | 0/9 | 1/3 | 0/3 | 0/11 | 0/6 | 10/29 | 2/28 |
| DiarrhoeaGastrointestinal disorders | 1/10 | 0/9 | 0/3 | 0/3 | 3/11 | 0/6 | 10/29 | 4/28 |
| Decreased appetiteMetabolism and nutrition disorders | 1/10 | 2/9 | 0/3 | 0/3 | 3/11 | 0/6 | 10/29 | 2/28 |
| Abdominal painGastrointestinal disorders | 1/10 | 1/9 | 1/3 | 0/3 | 3/11 | 1/6 | 2/29 | 0/28 |
| Dry skinSkin and subcutaneous tissue disorders | 2/10 | 2/9 | 1/3 | 0/3 | 0/11 | 0/6 | 2/29 | 0/28 |
Safety Population included all participants who received at least 1 dose of study drug and had a post-baseline observation.
| Age, Categorical(Participants) | Stage A: Setmelanotide 0.75 mg BID | Stage A: Setmelanotide 1.5 mg QD | Stage A: Placebo 0.75 mg BID | Stage A: Placebo 1.5 mg QD | Stage B: Setmelanotide 1.5 mg QD | Stage B: Placebo 1.5 mg QD | Stage C: Setmelanotide 2 mg QD | Stage C: Placebo 2 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 10 | 9 | 3 | 3 | 11 | 6 | 29 | 28 | 99 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Stage A: Setmelanotide 0.75 mg BID | Stage A: Setmelanotide 1.5 mg QD | Stage A: Placebo 0.75 mg BID | Stage A: Placebo 1.5 mg QD | Stage B: Setmelanotide 1.5 mg QD | Stage B: Placebo 1.5 mg QD | Stage C: Setmelanotide 2 mg QD | Stage C: Placebo 2 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 6 | 3 | 1 | 1 | 5 | 4 | 21 | 18 | 59 |
| Male | 4 | 6 | 2 | 2 | 6 | 2 | 8 | 10 | 40 |
| Ethnicity (NIH/OMB)(Participants) | Stage A: Setmelanotide 0.75 mg BID | Stage A: Setmelanotide 1.5 mg QD | Stage A: Placebo 0.75 mg BID | Stage A: Placebo 1.5 mg QD | Stage B: Setmelanotide 1.5 mg QD | Stage B: Placebo 1.5 mg QD | Stage C: Setmelanotide 2 mg QD | Stage C: Placebo 2 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 5 | 2 | 0 | 1 | 2 | 3 | 3 | 17 |
| Not Hispanic or Latino | 9 | 4 | 1 | 3 | 10 | 4 | 26 | 25 | 82 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Stage A: Setmelanotide 0.75 mg BID | Stage A: Setmelanotide 1.5 mg QD | Stage A: Placebo 0.75 mg BID | Stage A: Placebo 1.5 mg QD | Stage B: Setmelanotide 1.5 mg QD | Stage B: Placebo 1.5 mg QD | Stage C: Setmelanotide 2 mg QD | Stage C: Placebo 2 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 2 |
| Black or African American | 8 | 4 | 1 | 2 | 5 | 4 | 11 | 9 | 44 |
| White | 2 | 4 | 1 | 1 | 6 | 2 | 13 | 17 | 46 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 2 | 6 |
| Region of Enrollment(participants) | Stage A: Setmelanotide 0.75 mg BID | Stage A: Setmelanotide 1.5 mg QD | Stage A: Placebo 0.75 mg BID | Stage A: Placebo 1.5 mg QD | Stage B: Setmelanotide 1.5 mg QD | Stage B: Placebo 1.5 mg QD | Stage C: Setmelanotide 2 mg QD | Stage C: Placebo 2 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|
| United States | 10 | 9 | 3 | 3 | 11 | 6 | 29 | 28 | 99 |
Ran from Jan 2014 to primary completion in Aug 2014, 7 months.
Results were first posted in Aug 2023, 9 years after primary completion. A results delay was requested in Apr 2015.
Of 62 phase 1/2 interventional studies under Obesity, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Setmelanotide
Rhythm Pharmaceuticals, Inc. →